Meta’s AI Tools Can Benefit From DeepSeek, Citi Says. Here’s Why.
Chinese company DeepSeek is shaking up the artificial-intelligence scene, but that could mean good things for Meta Platforms, ...
Citi Analyst Maintains Buy Rating on NVIDIA (NVDA) with $175 Price Target, Addresses Competition Concerns
We recently compiled a list of the 10 Important AI News and Ratings for Today. In this article, we are going to take a look ...
Citi is shaking up its technology leadership and reorganizing its 'crown jewel' services unit
Leaders in Citi's technology unit and its "crown jewel" services unit announced a raft of changes as key leaders step down.
Citi Analysts Say Trump Can’t Reverse Energy Transition
The policies of President Donald Trump will fail to hold back progress in transitioning away from high-carbon energy sources, ...
Brokerage Radar: Citi lowers Colgate's target, Jefferies upgrades Kaynes to Buy
Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes SBI Card, ...
Merck price target lowered to $125 from $130 at Citi
Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...
ASX near record; Citi, Westpac join call for Feb rate cut
ASX rises; banks clash on Feb rate cut forecasts, core and headline CPI overshoot expectations; Boss Energy soars; Star offloads Sydney sites.
CNBC1d
The best Citi credit cards for earning cash back and paying off debt — plus one with no late fees
Citi is an advertising partner. Select may receive an affiliate commission when you click on the links for products from our partners. This commission does not influence the opinions ...
Nvidia sees DeepSeek as newer opportunity catalyst, says Citi
Citi analyst Atif Malik says that according to a statement given to Bloomberg, Nvidia (NVDA) views DeepSeek’s latest models as an “excellent AI ...
Citi raises Akero Therapeutics stock target to $80 on EFX data
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...